Related Experiment Video
Updated: Feb 20, 2026

09:07
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
Published on: May 27, 2015
11.1K
Adenosine-Specific Transcriptional Programs in Murine Connective Tissue-Type Mast Cells
Qihua Liang1,2, Volodymyr Tsvilovskyy1,2, Anouar Belkacemi1,2
1Institute of Pharmacology, Heidelberg University, 69120 Heidelberg, Germany.
ACS Pharmacology & Translational Science
|February 19, 2026
Summary
Adenosine (ADO) uniquely activates mast cells to synthesize new inflammatory mediators, distinct from typical degranulation responses. This discovery reveals a novel pathway for ADO-mediated inflammation in immune cells.
Area of Science:
- Immunology
- Molecular Biology
Background:
- Mast cells are key immune cells in allergic and inflammatory diseases.
- Adenosine (ADO) activates mast cells but its role in de novo mediator synthesis is unclear.
Purpose of the Study:
- To identify the specific gene expression program activated by ADO in mast cells.
- To compare ADO's effects with known mast cell activators like antigens and Mrgprb2 agonists.
Main Methods:
- Bulk RNA sequencing of primary murine peritoneal mast cells (PMCs).
- Comparative analysis of gene expression induced by ADO, compound 48/80, and FcεRI activation.
- Bioinformatic analyses including transcription factor activity, functional enrichment, and network analysis.
Main Results:
- Identified 393 genes uniquely regulated by ADO stimulation.
- Discovered ADO induces de novo synthesis of transforming growth factor α and interleukin 7.
- Revealed an ADO-specific gene program involving phosphoinositide signaling, glycolysis, and cell cycle arrest.
Conclusions:
- ADO triggers a unique transcriptional program in mast cells, independent of degranulation.
- ADO-induced de novo mediators represent a novel mechanism in mast cell-mediated inflammation.
- Further studies can explore the functional role of these mediators in ADO-driven inflammatory reactions.
Related Concept Videos
Adrenergic Receptors: β Subtype
4.0K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.0K
Master Transcription Regulators
7.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.9K
Adrenergic Receptors: ɑ Subtype
3.1K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.1K

